Please login to the form below

Not currently logged in
Email:
Password:

Novartis to submit Afinitor for approval

Novartis is to submit its advanced breast cancer drug Afinitor for marketing approval following positive results from a phase III study

Novartis is to submit its advanced breast cancer drug Afinitor (everolimus) for marketing approval following positive results from a phase III study.

The BOLERO-2 was stopped early after interim results showed that the primary end point of significant progression-free survival compared to placebo plus exemestane had already been met.

The study involved postmenopausal women with estrogen receptor-positive locally-advanced or metastatic breast cancer, whose disease has progressed, despite initial endocrine therapy.

Hervé Hoppenot, president, Novartis Oncology, described how woman can develop resistance to endocrine therapy, and that there is a "significant need" for new treatment options.

He said: "Based on these study results, this combination has the potential to extend the time until chemotherapy is needed for these patients."

Novartis has said it will present the results at an upcoming medical conference, with plans for regulatory approval submission to be submitted by the end of 2011.

5th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics